The risk of type 2 diabetes mellitus in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Eun Bin | - |
dc.contributor.author | Han, Kyungdo | - |
dc.contributor.author | Jung, Jin-Hyung | - |
dc.contributor.author | Chung, Yeon Hak | - |
dc.contributor.author | Kwon, Soonwook | - |
dc.contributor.author | Park, Junhee | - |
dc.contributor.author | Jin, Sang-Man | - |
dc.contributor.author | Shin, Dong Wook | - |
dc.contributor.author | Min, Ju-Hong | - |
dc.date.accessioned | 2024-05-02T02:00:22Z | - |
dc.date.available | 2024-05-02T02:00:22Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.issn | 2211-0348 | - |
dc.identifier.issn | 2211-0356 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/49529 | - |
dc.description.abstract | Background and objectives: An association has been suggested between premorbid type 2 diabetes mellitus (T2DM) and the risk of multiple sclerosis (MS). However, little is known about the risk of developing T2DM in MS and neuromyelitis optica spectrum disorder (NMOSD). This study aimed to determine the T2DM risk in patients with MS and NMSOD. Methods: The Korean National Health Insurance Service database was analyzed, and 1,801 and 1,721 adults with MS and NMOSD, respectively, who were free of T2DM between January 2010 and December 2017, were included. Matched controls were selected based on age, sex, and the presence of hypertension and dyslipidemia. Results: The risk of developing T2DM was 1.54 times higher in NMOSD than in the controls (adjusted hazard ratio [aHR], 95 % confidence interval [CI] = 1.20–1.96). However, increased T2DM risk was not observed in MS (aHR = 1.13, 95 % CI = 0.91–1.42). The T2DM risk in patients with NMOSD was higher in those who received steroid treatment (aHR = 1.77, 95 % CI = 1.36–2.30) but not in those who did not (aHR = 0.59, 95 % CI = 0.24–1.43, p for interaction = 0.02). Discussion: T2DM risk was increased in NMOSD but not in MS. Administering steroid treatment to patients with NMOSD may increase their T2DM risk. © 2024 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | The risk of type 2 diabetes mellitus in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.msard.2024.105519 | - |
dc.identifier.bibliographicCitation | Multiple Sclerosis and Related Disorders, v.85 | - |
dc.identifier.wosid | 001202443300001 | - |
dc.identifier.scopusid | 2-s2.0-85187015948 | - |
dc.citation.title | Multiple Sclerosis and Related Disorders | - |
dc.citation.volume | 85 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S2211034824000981?via%3Dihub | - |
dc.publisher.location | 영국 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.subject.keywordAuthor | Asia | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | Multiple sclerosis | - |
dc.subject.keywordAuthor | Neuromyelitis optica spectrum disorder | - |
dc.subject.keywordAuthor | Risk | - |
dc.subject.keywordPlus | INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | DIAGNOSTIC-CRITERIA | - |
dc.subject.keywordPlus | DISABILITY | - |
dc.subject.keywordPlus | COMORBIDITY | - |
dc.subject.keywordPlus | RELAPSES | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Soongsil University Library 369 Sangdo-Ro, Dongjak-Gu, Seoul, Korea (06978)02-820-0733
COPYRIGHT ⓒ SOONGSIL UNIVERSITY, ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.